Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the announcement that its placement agreement for up to 145 million new shares, aimed at raising HKD 60.18 million, has lapsed due to unmet conditions by September 11 [1] Group 1: Company Announcement - Pioneer Pharma announced that the placement agreement has become invalid, but the board believes this will not have a significant adverse impact on the company's current operations and financial status [1] - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1] Group 2: Market Reaction - As of the report, Pioneer Pharma's stock price fell by 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1]
港股异动 | 领航医药生物科技(00399)跌超19% 1.45亿新股配售协议失效